Johnson & Johnson plans to submit a US filing for supplemental approval in Crohn’s disease for Tremfya before the end of 2024, a plan bolstered by Phase III data demonstrating head-to-head superiority to the firm’s older drug Stelara, but on the market J&J will also have to contend with AbbVie Inc.’s Skyrizi, which analysts say offers better efficacy in Crohn’s.
Tremfya Shows Head-To-Head Edge Versus Stelara In Crohn’s
Johnson & Johnson tested Tremfya against its established Stelara as the “benchmark” in IBD. Tremfya, already up for approval in ulcerative colitis, is planned for filing in Crohn’s later in 2024.